Navigating 10 Analyst Ratings For Geron

Geron GERN has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $5.3, a high estimate of $10.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 32.5% increase from the previous average price target of $4.00.

Breaking Down Analyst Ratings: A Detailed Examination

The perception of Geron by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Geron. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Geron compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Geron's stock. This examination reveals shifts in analysts' expectations over time.

Capture valuable insights into Geron's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Geron analyst ratings.

Unveiling the Story Behind Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Financial Milestones: Geron's Journey

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Challenges: Geron's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -77.67%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Geron's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -225969.57%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Geron's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -19.3%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Geron's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.88%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.35, Geron adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.